1 min read|61 words
US lawmakers have called on HHS to enforce Eli Lilly's participation in the 340B drug discount program, which provides discounted medications to safety-net hospitals serving vulnerable populations. The dispute highlights tensions between manufacturers and healthcare institutions over drug access and pricing. Read our analysis of what this means for patients, clinicians, and policy.
Read the full article on GMJ Newsroom →
Was this article helpful?
